Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.

Studied

Two phase 3 randomized trials comparing tirzepatide with placebo for obstructive sleep apnea and obesity.

Who / model

Adults with moderate-to-severe sleep apnea and obesity, studied for 52 weeks. One trial enrolled people without airway-pressure therapy at baseline; the other enrolled users. Participant counts are not stated.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

The primary breathing-disruption measure fell 25.3 versus 5.3 events per hour in the first trial, and 29.3 versus 5.5 in the second. Secondary outcomes, including weight, sleep symptoms and systolic blood pressure, also improved. Digestive adverse events were most frequent and generally mild or moderate.

Limits

Study limitations were not stated in the abstract. Methodological quality has not been appraised.

Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary